Pfizer Inc. (PFE) Thursday said it has completed the licensing agreement with 3SBio, Inc. for exclusive rights to develop and sell 3SBio's SSGJ-707.
As per the deal, 3SBio will receive $1.25 billion, and Pfizer will also make a $100 million equity investment in 3SBio. Additionally, Pfizer gets the option to extend the license to include exclusive development and commercialization rights to SSGJ-707 in China. In return, Pfizer will pay up to $150 million in option payments.
SSGJ-707, developed using 3SBio's proprietary CLF2 platform, is currently in various clinical studies in China for non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors. Positive interim results from the Phase 2 study of SSGJ-707 in patients with advanced NSCLC were recently reported.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.